The survey of Magnesium Sulfate in Prevention of Intraventricular Hemorrhage in Premature Infants

The survey of Magnesium Sulfate in Prevention of Intraventricular Hemorrhage in Premature Infants: Randomization Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016080729223N1

Enrollment

120

Registered

2016-10-03

Start date

2015-06-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Infants. Fetus and newborn affected by premature rupture of membranes

Interventions

Intervention 1: Intervention group: Intravenous Magnesium Sulfate with dose of 6 gram during 20 to 30 minutes. Intervention 2: Comparison group: without drug.

Prevention

Intervention group: Intravenous Magnesium Sulfate with dose of 6 gram during 20 to 30 minutes

Comparison group: without drug

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: who are have signed a consent form; Gestational age 34 weeks; Lack of Hypertension; Lack of Pre-eclampsia; Lack of congenital malformations. Exclusion criteria: Lack of consent for enter the study; having hypertension; having pre-eclampsia; having congenital malformations.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Intraventricular Hemorrhage. Timepoint: After the birth. Method of measurement: Cranial Ultrasonically.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mahsa Rezaei

Iran University of Medical Sciences

mahasa.rezaei@yahoo.com+98 21 6650 9283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 26, 2026